John M. Koomen, Ph.D. - Publications

2002 Texas A & M University, College Station, TX, United States 
Biological Mass Spectrometry

6 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Sumi NJ, Ctortecka C, Hu Q, Bryant AT, Fang B, Remsing Rix LL, Ayaz M, Kinose F, Welsh EA, Eschrich SA, Lawrence HR, Koomen JM, Haura EB, Rix U. Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets. Cell Chemical Biology. PMID 31257184 DOI: 10.1016/J.Chembiol.2019.06.003  0.4
2019 Palve V, Knezevic C, Luo Y, Li X, Novakova S, Welsh E, Fang B, Kinose F, Haura EB, Monteiro AN, Koomen JM, Lawrence HR, Rix U. Abstract B021: PARP16 is a novel target of talazoparib which contributes to synergy with adavosertib in SCLC Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B021  0.4
2018 Hill KS, Roberts ER, Wang X, Marin E, Park TD, Son S, Ren Y, Fang B, Yoder S, Kim S, Wan L, Sarnaik AA, Koomen JM, Messina JL, Teer JK, et al. PTPN11 plays oncogenic roles and is a therapeutic target for BRAF wild-type melanomas. Molecular Cancer Research : McR. PMID 30355677 DOI: 10.1158/1541-7786.Mcr-18-0777  0.4
2017 Sumi NJ, Fang B, Rix LL, Ayaz M, Kinose F, Welsh EA, Eschrich SA, Lawrence HR, Koomen JM, Haura EB, Rix U. Abstract 221: Integrated functional proteomics of MET/VEGFR inhibitors reveals complex mechanism of action of foretinib in NSCLC Cancer Research. 77: 221-221. DOI: 10.1158/1538-7445.Am2017-221  0.4
2016 Knezevic CE, Wright G, Remsing Rix LL, Kim W, Kuenzi BM, Luo Y, Watters JM, Koomen JM, Haura EB, Monteiro AN, Radu C, Lawrence HR, Rix U. Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. Cell Chemical Biology. PMID 27866910 DOI: 10.1016/J.Chembiol.2016.10.011  0.4
2015 Schneeberger VE, Ren Y, Luetteke N, Huang Q, Chen L, Lawrence HR, Lawrence NJ, Haura EB, Koomen JM, Coppola D, Wu J. Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma. Oncotarget. 6: 6191-202. PMID 25730908 DOI: 10.18632/Oncotarget.3356  0.4
Show low-probability matches.